Ofloxacin Ophthalmic

Introduction Overview

Generic Name

ofloxacin ophthalmic

Brand Name

Ocuflox

Dosage Form

ophthalmic solution (0.3%)

Drug Class

ophthalmic anti-infectives

Pharmacokinetics

Absorption: Ofloxacin ophthalmic solution is administered topically to the ocular surface, leading to localized absorption primarily through the cornea and conjunctiva. The drug achieves therapeutic concentrations in the aqueous humor and other ocular tissues with minimal systemic absorption. Studies indicate that systemic bioavailability after ocular administration is negligible, reducing the risk of systemic adverse effects.

Distribution: Upon topical ocular instillation, ofloxacin distributes predominantly within the anterior segment of the eye including the cornea, conjunctiva, aqueous humor, and to some extent the eyelids. Concentrations in the vitreous humor and posterior segment are minimal due to limited penetration. The distribution is influenced by the integrity of the corneal epithelium, with increased penetration in the presence of corneal ulceration or inflammation.

Metabolism: Ofloxacin is largely metabolized hepatically when administered systemically, but given the minute systemic absorption from ophthalmic application, metabolism plays a minor role. Any absorbed drug is metabolized primarily in the liver via oxidative pathways, forming metabolites with diminished antibacterial activity.

Elimination: Systemically absorbed ofloxacin is primarily excreted unchanged in the urine. However, ocular administration results in minimal systemic levels; hence, elimination is minimal via renal or biliary routes following ophthalmic use. The drug and its residues on the ocular surface are cleared through tear turnover and nasolacrimal drainage, which may impact dosing frequency and local drug concentration.

Dosage Forms

Available Dosage Forms: Ofloxacin ophthalmic is available as a sterile ophthalmic solution with a concentration of 0.3%. This is supplied typically in multi-dose plastic bottles with an eye dropper tip designed for accurate administration.

Dosages for Adults and Adolescents: For bacterial conjunctivitis, the recommended initial dosing in adults and adolescents aged 1 year and older is 1 to 2 drops instilled into the affected eye(s) every 2 to 4 hours for the first two days. From days 3 to 7, dosing is reduced to 1 to 2 drops four times daily. For corneal ulcers, intensive therapy involves instillation of 1 to 2 drops every 30 minutes while awake during the first two days and also 4 and 6 hours after retiring. This is followed by dosing every hour while awake through days 3 to 7 to 9, then tapering to 1 to 2 drops four times daily until completion of treatment.

Specific Patient Populations: Pediatric patients aged 1 year and older follow dosing regimens similar to adults, with careful administration under medical supervision. Use in infants younger than 1 year is not approved due to lack of established safety data. Use during pregnancy and lactation has not been fully studied; thus, it should be administered only if clearly needed and under specialist guidance. Patients with compromised corneal integrity may absorb increased amounts of the drug, potentially requiring dosing adjustments and close monitoring.

Mechanism Of Action

Ofloxacin is a synthetic fluoroquinolone antibiotic acting by inhibiting bacterial DNA gyrase and topoisomerase IV, essential enzymes for bacterial DNA replication, transcription, repair, and recombination. By disrupting these enzymes, ofloxacin impairs bacterial DNA supercoiling, leading to interruption of DNA processes and ultimately bacterial cell death.

At the cellular level, ofloxacin exhibits bactericidal activity against a broad spectrum of Gram-positive and Gram-negative bacteria, including common ocular pathogens such as Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, and Haemophilus influenzae. Its ability to target both DNA gyrase and topoisomerase IV reduces the risk of bacterial resistance development compared to agents targeting only one enzyme.

Biochemically, ofloxacin binds to the enzyme-DNA complex, stabilizing it and preventing the resealing of DNA breaks that occur during normal enzymatic activity. This leads to accumulation of double-stranded DNA breaks, activation of cellular death pathways, and bacterial cell lysis. The ophthalmic formulation delivers adequate concentrations to the ocular tissues to exert these effects effectively, facilitating resolution of bacterial infections.

Clinically, ofloxacin’s mechanism translates to effective management of bacterial conjunctivitis and corneal ulcers caused by susceptible organisms. Compared to older antibiotics, fluoroquinolones like ofloxacin offer advantages including broad spectrum coverage, rapid bactericidal activity, and convenient dosing schedules. Clinical trials and practice guidelines support its use as a first or second-line therapy for ocular bacterial infections, with ongoing research into resistance patterns informing optimal treatment protocols.

Pharmacological Actions

Bactericidal activity against a broad spectrum of ocular bacterial pathogens.
Inhibition of bacterial DNA gyrase and topoisomerase IV enzymes.
Disruption of bacterial DNA replication and repair mechanisms.
Effective penetration into anterior segment ocular tissues.
Reduction of bacterial load in conjunctivitis and corneal ulcer infections.
Provides rapid symptomatic relief by controlling infection.
Overcomes resistance mechanisms encountered in older antibiotics.
Minimal systemic absorption reducing systemic side effect potential.
Preservation of activity against both Gram-positive and Gram-negative bacteria.
Can be used in intensive dosing for serious ocular infections like corneal ulcers.

Therapeutic Or Clinical Uses

Treatment of bacterial conjunctivitis caused by susceptible bacteria including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Haemophilus influenzae, and Pseudomonas aeruginosa.
Management of bacterial corneal ulcers due to organisms such as Staphylococcus aureus, Streptococcus pneumoniae, Pseudomonas aeruginosa, Serratia marcescens, and Propionibacterium acnes.
Effective for ocular infections resistant or intolerant to other antibiotic classes.
Prophylactic use in certain ophthalmic surgeries to prevent postoperative infections (off-label usage).
Treatment of bacterial keratitis and keratoconjunctivitis requiring fluoroquinolone coverage.
Used in patients who are allergic or intolerant to other anti-infectives.
Treatment adjunct in severe ocular surface infections requiring frequent dosing.
Applicable in both adult and pediatric patient populations aged 1 year and older.
Preferred for infections where rapid bacterial eradication is desired.

Side Or Adverse Effects

Ocular burning, stinging, or irritation immediately following instillation.
Mild transient blurred vision.
Eye pain or discomfort.
Eye redness, itching, or watering.
Eyelid redness and puffiness.
Ocular dryness and foreign body sensation.
Increased sensitivity of the eyes to light (photophobia).
Potential for serious allergic reactions, including hives and facial swelling.
Severe ocular reactions such as crusting, discharge, or eye swelling indicating possible secondary infection or hypersensitivity.
Rare occurrence of severe skin reactions including Stevens-Johnson syndrome characterized by fever, sore throat, and widespread rash with blistering and peeling.
Discoloration of soft contact lenses due to preservatives in the formulation.
Risk of contamination-related infection if dropper tip contacts eye or surfaces.
Uncommon but possible systemic effects are negligible due to low systemic absorption.
Temporary discomfort that usually resolves with continued therapy.
Potential transient visual disturbances impacting activities requiring clear vision.

Precautions

Do not use if allergic to ofloxacin or any fluoroquinolones (e.g., ciprofloxacin, levofloxacin, moxifloxacin).
Avoid use for viral or fungal eye infections as it is ineffective against these pathogens.
Use caution in pregnant or breastfeeding women; safety has not been established.
Do not administer to children under 1 year of age due to insufficient safety data.
Avoid contamination of the dropper tip to prevent secondary eye infections.
Remove contact lenses prior to administration and wait at least 15 minutes before reinsertion.
Use the medication exactly as prescribed to avoid resistance development and treatment failure.
Patients with corneal ulcers may require intense dosing and close follow-up.
Avoid use of other topical eye medications unless approved by a healthcare provider.
Monitor for signs of hypersensitivity or severe ocular reactions and report promptly.
Store at room temperature, protect from moisture and heat; do not freeze.
In case of medication discoloration or particulate matter in solution, do not use and obtain replacement.
Use with caution in patients with ocular surface disease that may increase absorption.
Inform healthcare providers about all concurrent medications to avoid drug interactions.
Patients should be advised that the white buildup on ulcers during treatment is a sign of medication effectiveness, not an adverse effect.

Warnings

Discontinue use and seek immediate medical attention if signs of severe allergic reaction occur such as rash, swelling, or difficulty breathing.
Serious ocular adverse effects including increased pain, swelling, redness, or discharge require urgent evaluation.
Avoid use in the presence of viral or fungal eye infections to prevent worsening or mismanagement.
Not intended for systemic use; accidental ingestion should be managed promptly according to poisoning protocols.
May cause transient blurred vision impairing the ability to perform hazardous tasks such as driving or operating machinery.
The preservative in the solution may discolor soft contact lenses; contact lens use should be avoided during therapy.
Risk of secondary infection if the dropper tip contaminates the eye or surrounding surfaces.
Not established for use in children under one year; safety and efficacy not demonstrated.
Use with caution if patient has history of hypersensitivity to other quinolones.
Do not share medication to prevent cross-contamination and spread of infections.
Special vigilance required when treating corneal ulcers due to risk of vision loss if inadequately treated.
Follow prescribed dosing schedule strictly to avoid development of bacterial resistance.
Report unusual or worsening eye symptoms promptly to healthcare provider.
Store and handle medication properly to maintain sterility and efficacy.
If symptoms worsen or persist beyond prescribed treatment duration, seek re-evaluation.

Contraindication

Known hypersensitivity to ofloxacin or other fluoroquinolone antibiotics.
History of allergic reactions to any component of the ophthalmic formulation.
Use in viral eye infections such as herpes simplex keratitis.
Use in fungal infections of the eye.
Patients under 1 year of age due to unestablished safety.
Use in patients with hypersensitivity to preservatives present in the ophthalmic solution, if known.
Avoid in patients with previous severe adverse reactions to fluoroquinolone ophthalmic agents.

Drug Interactions

Potential interaction with other topical ophthalmic medications when administered concurrently; stagger dosing by at least 10 minutes.
No significant systemic drug interactions reported due to minimal systemic absorption.
Concurrent use with other fluoroquinolones is generally not recommended to avoid additive toxicity.
No clinically significant interaction expected with systemic medications at typical topical ophthalmic doses.
Use caution with medications that may cause photosensitivity when combined with quinolones though systemic exposure is minimal.
Drugs that alter tear production or ocular surface integrity may affect drug penetration and efficacy.
Inform healthcare provider of all medications, including over-the-counter and herbal products.
No evidence of interaction with contact lens wear; however, lenses must be removed during administration.
No known interactions with systemic anticoagulants or antiplatelet agents at ophthalmic dose.
No impact on systemic cytochrome P450 enzyme pathways is anticipated from topical application.

Preparations Of The Drug

Ofloxacin ophthalmic solution 0.3% sterile drops in multi-dose plastic bottles.
Contains preservatives such as benzalkonium chloride which may affect contact lens wear.
Formulated to provide stable, isotonic, pH-balanced solution suitable for ocular administration.
Available in 5 mL and 10 mL bottles for outpatient use.
Includes a dropper tip designed to minimize contamination risk and allow accurate dosing.
Packaged with detailed instructions for storage and use to maintain sterility.
Should be stored at room temperature (controlled room temperature) away from heat and moisture.
Supplied under brand name Ocuflox as well as generic equivalents.
Dispensed with patient counseling instructions emphasizing hygiene and dosing compliance.
No oral or parenteral forms approved for ophthalmic use; systemic formulations available separately.